APRI score is not predictive of post-surgical outcomes in cholangiocarcinoma patients.

BACKGROUND: Cholangiocarcinoma is an epithelial malignancy of the intrahepatic or extrahepatic biliary tree, primarily driven by chronic inflammation and fibrosis. Fibrosis has been shown to correlate with malignancy, and the aminotransferase-platelet ratio index (APRI) score, a marker for hepatic fibrosis, has proved useful in prognosticating hepatocellular carcinoma. This study aimed to assess the utility of APRI score in predicting post-surgical outcomes in cholangiocarcinoma patients.

METHODS: Clinical data from a total of 152 cholangiocarcinoma patients who underwent surgical resection at the Mayo Clinic were collected. The data were subsequently analyzed to determine if there was a relationship between APRI score and the demographic, laboratory, pathologic and outcome data, including overall survival. To determine the relationship between quantitative and qualitative data and the APRI score, a P-value <0.05 was considered as statistically significant.

RESULTS: No relationship between APRI score and demographic factors was identified. There were correlations between APRI score and alanine transaminase, albumin and bilirubin, but the remaining laboratory parameters showed no correlation. APRI score did not prove to be useful as a prognostic tool, as it did not correlate with tumor pathology features (tumor grade t -test P=0.86, N stage ANOVA P=0.94, vascular invasion t -test P=0.59, and perineural invasion t -test P=0.14), or with post-surgical recurrence ( t -test P=0.22) and mortality ( t -test P=0.39).

CONCLUSION: APRI score is not a prognostic tool for post-surgical outcomes in patients with cholangiocarcinoma.